A randomized, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 48 weeks of once daily treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5 µg] and 10 µg [2 actuations of 5 µg ]) delivered by Respimat Inhaler, and 48 weeks of twice daily Foradil (12 µg) delivered by the Aerolizer Inhaler, in patients with Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A randomized, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 48 weeks of once daily treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5 µg] and 10 µg [2 actuations of 5 µg ]) delivered by Respimat Inhaler, and 48 weeks of twice daily Foradil (12 µg) delivered by the Aerolizer Inhaler, in patients with Chronic Obstructive Pulmonary Disease (COPD)

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Olodaterol (Primary) ; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 24 May 2017 Results assessing long-term safety profile of olodaterol from NCT00793624 and NCT00796653 trials presented at the 113th International Conference of the American Thoracic Society
    • 11 Sep 2013 Pooled safety analysis results presented at the 23rd Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top